Medical professionals have identified five distinct forms of pancreatitis in Ozempic users, each carrying different prognoses: Acute Pancreatitis : The most common form, affecting 80% of cases, characterized by sudden inflammation that typically resolves but can trigger lasting motility disorders with mortality rates below 2% in mild cases Necrotizing Pancreatitis : Occurring in 20-30% of severe cases, involving tissue death within the pancreas that increases the risk of permanent gastroparesis, with mortality rates ranging from 15-30% Hemorrhagic Pancreatitis : A severe variant specifically mentioned in FDAs 2025 updated warnings, involving bleeding within the pancreas and carrying mortality rates exceeding 30% Chronic Pancreatitis : Progressive inflammation leading to permanent scarring and dysfunction, strongly associated with persistent gastroparesis development The FDAs January 2025 update to the ozempic warning label specifically added warnings about fatal and non-fatal hemorrhagic or necrotizing pancreatitis and other serious adverse events including anterior ischemic optic neuropathy, acknowledging the serious nature of these complications

Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study
As you lose weight, your body requires fewer calories to maintain its new, lower weight
I am cautious to add Naltrexone to that list because I have seen a depressed mood when used for weight loss
Gastrointestinal Effects Gastrointestinal symptoms represent the most common side effects for both medications